Modular Technology Project Considerations
10:15am – 11:30am

Modular design and construction has long been considered a novelty in the pharmaceutical and biotech industries. As companies mature and expand, modular design is becoming accepted as an increasingly popular alternative for designing, building and expanding facilities. The pre-engineered design allows companies to immediately put a facility into use and quickly adapt with minimal installation and costly down time. Life sciences companies choose to go modular with labs and clean rooms that are able to meet thermal, chemical resistance, sound, and fire rated requirements; data centers that are quick-to-deploy, cost-effective and are energy efficient solution for high density computing environments; production of biological drug products. This presentation will use case studies from recently completed biopharmaceutical projects to provide an understanding of the benefits and challenges of modular construction, and how to best execute a modular project. It will also discuss the process to select what projects are most likely to benefit from a modular approach and provide ample time for questions and answers.

Panel Moderator:

Par Almhem
President, Pharmadule, Inc.

Panel Speakers:

Jamie Fettkether
Executive Vice President, Lockard Construction

Dan Palmer
General Manager, Art's-Way Scientific, Inc.

Trevor Richter
Vice President of Business Development, Stellar

Mark S. Romney
Research Facilities Planner, UC Davis Health System

Lessons Learned about Laboratory Costs from the CIRM Stem Cell Facility Grant Proposals
11:45am – 1:00pm

The California Institute for Regenerative Medicine (CIRM), the state's stem-cell agency, awarded $271 million this year to 12 universities and research institutions to build new stem-cell laboratories. On top of this, an additional $560 million was committed by donors and these 12 research organizations to building labs. All told, the $831 million will create nearly 800,000 square feet of new stem-cell research capacity over the next two years. By looking at the submissions that were presented to CIRM for the stem cells major facility grants, we can compare the designs and costs for 12 buildings that have essentially the same mission and similar programs. We will investigate the factors and dynamics that produced different cost factors for these buildings. How did location, site, design and delivery method all affect the final project cost? What lessons can life sciences companies glean from these projects?

Panel Speakers:

Gordon Beveridge
Executive Vice President, TBD Consultants

David Lichtenger
Chairman, CIRM Facilities Working Group
Integrated Facility Solutions

Greg Muth
Laboratory Architect, Perkins+Will

Systems & Tools for Managing Laboratory Equipment and Assets
2:45pm – 4:00pm

Emerging life science companies face many challenges associated with tracking equipment inventories and managing maintenance activities, resulting in poor productivity, lost equipment and escalating service and maintenance costs. A number of Northern California life science companies are the midst of dealing with these very challenges as they scale their operations. This session will discuss the real world challenges that these companies are facing (e.g. increasing number of equipment inventory items and components, multiple service providers and maintenance agreements, equipment relocations in light of facility expansion, and need for periodic inventory audits to improve accountability and controls) and the systems tools that it is using to address/solve them.

Panel Moderator:

Howard Weiss
Principal, Perkins+Will

Panel Speakers:

Ginny Kosor
Director of Facilities, FibroGen, Inc.

Jose Orellana
Purchasing Manager, Five Prime Therapeutics, Inc.

Mark Zuckerman
Director of EH&S and Facilities, Maxygen, Inc.